脂蛋白(a)是ASCVD的公认危险因素。仍然没有针对Lp（a）的靶向治疗，然而,像pelacarsen这样的药物,olpasiran,泽拉西兰,lepodisiran和muvalaplin正在进行临床试验，并已被证明可有效降低Lp（a）水平。此外，Lp(a)水平升高显著影响主动脉瓣置换术(AVR)和心脏移植术(HTx)后患者的预后。因此,对这些患者的Lp（a）浓度的评估将允许对他们的心血管风险进行更准确的分层，降低Lp(a)的可能性将允许优化这种风险。在这篇文章中,我们总结了关于Lp(a)和降脂治疗在AVR和HTx术后患者中的作用的最重要信息.
Lipoprotein(a) is a recognized risk factor for ASCVD. There is still no targeted therapy for Lp(a), however, drugs such as pelacarsen, olpasiran, zerlasiran, lepodisiran and muvalaplin are in clinical trials and have been shown to be effective in significantly reducing Lp(a) levels. Moreover, elevated Lp(a) levels significantly affect the prognosis of patients after aortic valve replacement (AVR) and heart transplantation (HTx). Therefore, the assessment of Lp(a) concentration in these patients will allow for a more accurate stratification of their cardiovascular risk, and the possibility of lowering Lp(a) will allow for the optimization of this risk. In this article, we summarized the most important information regarding the role of Lp(a) and lipid-lowering treatment in patients after AVR and HTx.
PDF(Pubmed)